CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian …
Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and
allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351
in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named
(Compassionate) Use Program. Sixty days treatment-related mortality was 7%(5/71). The
response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71
(8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was …
allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351
in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named
(Compassionate) Use Program. Sixty days treatment-related mortality was 7%(5/71). The
response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71
(8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was …
以上显示的是最相近的搜索结果。 查看全部搜索结果